Should You Buy Quest Diagnostics Ahead of Earnings?
DGX is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics: Buy Into Future Patient Demand, At An Undervalued Price Today
For my initial rating of Quest Diagnostics (DGX), I'm calling it a buy. Forecasts point to continuing demand for diagnostic testing, while the company also grew its business via acquisitions and new solutions. Strong profit margins, proven cashflow and dividend growth, and investment-grade credit ratings from major agencies are additional upside factors.
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
DGX rides on double-digit diagnostics growth and a wave of strategic acquisitions despite rising debt and policy headwinds.
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DGX Stock Up on New Blood Test Development Deal With MD Anderson
DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
